Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.

Pierre Johansen,Jonas Håkan-Bloch,Aiden R Liu,Peter G Bech,Sofie Persson,Lawrence A Leiter

PharmacoEconomics - open（2019）

引用 17|浏览2

暂无评分

摘要

From a Canadian societal perspective, semaglutide may be a cost-effective treatment option versus dulaglutide in patients with T2D who are inadequately controlled on metformin monotherapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要